WHO ICTRP trial
A study of HM10560A, a long-acting growth hormone product, for treatment of…
EUCTR2011-001826-61-HU · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2011-001826-61-HU |
|---|---|
| Public title | A study of HM10560A, a long-acting growth hormone product, for treatment of adult patients suffering from growth hormone deficiency |
| Scientific title | A phase II, randomized, active controlled, open label study of safety and efficacy of HM10560A a Long-acting rhGH-HMC001 conjugate in treatment of subjects suffering from adult growth hormone deficiency (AGHD) |
| Primary sponsor | Hanmi Pharmaceutical Co., Ltd. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Serbia;Hungary;Poland;Ukraine;Romania;Russian Federation;Bulgaria;Korea, Republic of;India |
| Conditions | Adult growth hormone deficiency (AGHD) MedDRA version: 18.0 Level: PT Classification code 10056438 Term: Growth hormone deficiency System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] |
| Interventions | Product Name: HM10560A Product Code: HM10560A Pharmaceutical Form: Solution for injection Current Sponsor code: HM10560A Other descriptive name: chemical conjugate of recombinant human growth hormone (rhGH) and human immunoglobulin G4… |
| Registration date | May 23, 2011 |
| Target size | 65 |
| Secondary IDs | 11-HM10560A-201 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: